Boston Scientific Acquires Valencia Technologies to Enhance Bladder Treatment Solutions

Revolutionizing Bladder Treatment: Boston Scientific’s Strategic Acquisition

Boston Scientific Corporation announces its definitive agreement to acquire Valencia Technologies Corporation, a move that underscores the company’s commitment to enhancing its urology offerings. Valencia Technologies specializes in innovative solutions for bladder dysfunction, particularly addressing the needs of individuals suffering from overactive bladder (OAB), a condition that affects nearly 30 million adults aged 40 and older in the United States. The acquisition is expected to expand Boston Scientific's capabilities in implantable tibial nerve stimulation (ITNS) technology, essential for treating urge urinary incontinence (UUI), a significant symptom of OAB.

The centerpiece of Valencia Technologies’ offerings is its FDA-approved eCoin® System, a small implantable device designed for patients who have not responded to conventional treatments. This device, implanted near the ankle, has shown promising results in clinical trials, with 68% of participants achieving at least a 50% reduction in UUI episodes after implantation. The acquisition will allow Boston Scientific to integrate the eCoin System into its existing pelvic health portfolio, providing a broader spectrum of treatment options for patients suffering from bladder dysfunction. Meghan Scanlon, Senior Vice President and President of Urology at Boston Scientific, emphasizes that this strategic acquisition complements the company's mission to improve patient health and reduce healthcare costs through innovative medical solutions.

Pending customary closing conditions, the acquisition is anticipated to be finalized in the first half of 2026. While it is projected to have a minor impact on the company's adjusted earnings per share, the acquisition may lead to more extensive dilution on a GAAP basis due to associated costs. Boston Scientific has maintained its status as a leader in medical technology for over 45 years, focusing on delivering innovative solutions that address critical health challenges. By incorporating Valencia Technologies' expertise and products, the company aims to reinforce its position in the urology market and elevate the standard of care for patients with bladder dysfunction.

In related developments, Par Health, Inc. appoints Dr. William Larkins as Executive Vice President and Chief Scientific Officer to revitalize its sterile injectables segment. With over 30 years of experience, Larkins is expected to drive advancements in the company's R&D pipeline. Meanwhile, TetraScience collaborates with Thermo Fisher Scientific to enhance biopharmaceutical research efficiency through AI integration, aiming to transform scientific data into actionable insights that improve therapy development and patient outcomes. These strategic moves within the healthcare sector reflect a broader trend toward innovation and efficiency in addressing complex medical challenges.